These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35335001)

  • 21. Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India.
    Basavaraja CK; Sebastian J; Ravi MD; John SB
    Ther Adv Vaccines Immunother; 2021; 9():25151355211055833. PubMed ID: 34841193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021.
    Hause AM; Gee J; Baggs J; Abara WE; Marquez P; Thompson D; Su JR; Licata C; Rosenblum HG; Myers TR; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(31):1053-1058. PubMed ID: 34351881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Active surveillance of adverse events following COVID-19 vaccines in a tertiary care hospital.
    Cherian NM; Durai DA; Jaisel M; Sharma D; Sebastian J; Basavaraja CK; Mathew M
    Ther Adv Vaccines Immunother; 2023; 11():25151355231193975. PubMed ID: 37641637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mild Adverse Events of Sputnik V Vaccine in Russia: Social Media Content Analysis of Telegram via Deep Learning.
    Jarynowski A; Semenov A; Kamiński M; Belik V
    J Med Internet Res; 2021 Nov; 23(11):e30529. PubMed ID: 34662291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Qualitative Assessment of Early Adverse Effects of Pfizer-BioNTech and Sinopharm COVID-19 Vaccines by Telephone Interviews.
    Abu-Halaweh S; Alqassieh R; Suleiman A; Al-Sabbagh MQ; AbuHalaweh M; AlKhader D; Abu-Nejem R; Nabulsi R; Al-Tamimi M; Alwreikat M; Alnouti M; Suleiman B; Yousef M; Jarbeh ME; Al-Shudifat AE; Alqassieh A; Bsisu I
    Vaccines (Basel); 2021 Aug; 9(9):. PubMed ID: 34579187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and types of adverse events during mass vaccination campaign with the meningococcal a conjugate vaccine (MENAFRIVAC™) in Cameroon.
    Ateudjieu J; Stoll B; Nguefack-Tsague G; Yakum MN; Mengouo MN; Genton B
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1170-1178. PubMed ID: 27174237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Retrospective Evaluation of Self-Reported Adverse Events Following Immunization with Different COVID-19 Vaccines in Türkiye.
    Büyüker SM; Sultana A; Chowdhury JA; Chowdhury AA; Kabir S; Amran MS
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.
    ;
    MMWR Morb Mortal Wkly Rep; 2021 Jan; 70(2):46-51. PubMed ID: 33444297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.
    Gee J; Marquez P; Su J; Calvert GM; Liu R; Myers T; Nair N; Martin S; Clark T; Markowitz L; Lindsey N; Zhang B; Licata C; Jazwa A; Sotir M; Shimabukuro T
    MMWR Morb Mortal Wkly Rep; 2021 Feb; 70(8):283-288. PubMed ID: 33630816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flu vaccination in multiple sclerosis patients: a monocentric prospective vaccine-vigilance study.
    Maniscalco GT; Scavone C; Moreggia O; Di Giulio Cesare D; Aiezza ML; Guglielmi G; Longo G; Maiolo M; Raiola E; Russo G; Capuano A
    Expert Opin Drug Saf; 2022 Jul; 21(7):979-984. PubMed ID: 35189777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety profile of COVID-19 vaccinations in the United States.
    Singh A; Khillan R; Mishra Y; Khurana S
    Am J Infect Control; 2022 Jan; 50(1):15-19. PubMed ID: 34699960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-marketing safety surveillance for inactivated Enterovirus 71 vaccines in Jiangsu, China from 2017 to 2019.
    Gao J; Tang F; Wang Z; Yu J; Hu R; Liu L; Kang G
    Vaccine; 2021 Mar; 39(9):1415-1419. PubMed ID: 33541795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Participant-Centered Online Active Surveillance for Adverse Events Following Vaccination in a Large Clinical Trial: Feasibility and Usability Study.
    Munnoch SA; Cashman P; Peel R; Attia J; Hure A; Durrheim DN
    J Med Internet Res; 2019 Oct; 21(10):e14791. PubMed ID: 31647470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Cross-Sectional Study to Assess mRNA-COVID-19 Vaccine Safety among Indian Children (5-17 Years) Living in Saudi Arabia.
    Ahsan M; Shaik RA; Mallick AK; Banawas SS; Alruwaili TAM; Alanazi YA; Alzahrani HS; Ahmad RK; Ahmad MS; AlAnazi FH; Alfhaid F; Aljulifi MZ; Mehta V; Almhmd AE; Daham ASDA; Alruwaili MMM
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of safety and adverse events following COVID-19 vaccination and their predictors in first 30 days among healthcare workers of a tertiary care teaching hospital in North India.
    Bashar MA; Kamble B; Kumar S; Nandekar SV; Mathur SK
    Vaccine X; 2024 Aug; 19():100522. PubMed ID: 39077369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and preliminary efficacy of the Gam-COVID-Vac vaccine and outcomes of SARS-CoV-2 infection in Russian patients with genitourinary malignancies.
    Tsimafeyeu I; Volkova M; Alekseeva G; Berkut M; Nosov A; Myslevtsev I; Andrianov A; Semenov A; Borisov P; Zukov R; Goutnik V; Savchuk S; Dengina N; Mitin T
    J Hematol Oncol; 2021 Nov; 14(1):192. PubMed ID: 34774086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving community based AEFI (Adverse Events Following Immunization) reporting rate through telephone "beep" in a Cameroon health district: a randomized field trial.
    Tsafack M; Ateudjieu J
    Pan Afr Med J; 2015; 22():351. PubMed ID: 26985269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updates on Vaccine Safety and Post-Licensure Surveillance for Adverse Events Following Immunization in South Korea, 2005-2017.
    Yoon D; Kim JH; Lee H; Shin JY
    Yonsei Med J; 2020 Jul; 61(7):623-630. PubMed ID: 32608206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2021.
    Dooling K; Gargano JW; Moulia D; Wallace M; Rosenblum HG; Blain AE; Hadler SC; Plumb ID; Moline H; Gerstein J; Collins JP; Godfrey M; Campos-Outcalt D; Morgan RL; Brooks O; Talbot HK; Lee GM; Daley MF; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1344-1348. PubMed ID: 34555007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.